Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia.
Pharmacodynamic studies have been used to establish the relationships between the administered dosage and the concentration of drugs and metabolites in the blood or tissues and that between these concentrations and pharmacological effects. Polymorphisms in the genes that encode drug-metabolizing enzymes, drug transporters and drug targets can affect a person's response to therapy and may affect the development of de novo or therapy-related leukaemias. The burgeoning field of pharmacogenomics elucidates inherited differences in drug metabolism and treatment response. Increasingly, pharmacodynamic and pharmacogenomic studies are being used to individualize therapy to enhance efficacy and reduce toxicity.
Pui
Ching Hon
CH
St Jude Children's Research Hospital, and the Colleges of Medicine and Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Relling
Mary V
MV
Evans
William E
WE
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D010088:Oxidoreductases / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics; D010599:Pharmacokinetics; D011110:Polymorphism, Genetic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D011955:Receptors, Drug / Q000235:genetics / Q000378:metabolism; D014166:Transferases / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D011955:Receptors, Drug; D010088:Oxidoreductases; D014166:Transferases